Church of PeptidesSearch
Tirzepatide · Chapter 2 of 6

The safety ledger stays open

Preclinical efficacy and toxicology

Can an encouraging graph settle safety?

Fictional scene

His badge changes to PRECLINICAL. Subject One watches a promising graph climb and starts applauding. Then Doctide opens the safety ledger. The applause stops. There is more than one kind of test to pass.

What changes here

Mouse efficacy experiments and rat safety testing answered different questions. The rat thyroid finding remained a warning. [1] [2]

Read the study details & dates
Reported 2018

The early animal signal

Mouse experiments assessed insulin secretion, glucose tolerance, food intake and body weight. These findings helped support development, but mouse responses cannot establish human benefit. [1]

Regulatory preclinical record

Not every animal study found the same thing

Rat carcinogenicity studies found thyroid C-cell tumors. A separate six-month transgenic-mouse study did not show tumorigenicity. Species, study design and exposure matter. [2]

What this does not establish

The exact dates of all toxicology studies were not established here. Reproductive-developmental findings are described separately in label section 8.1; the story does not invent pregnancies or losses for Subject One.

Original sources
  1. LY3298176 preclinical studies
  2. Mounjaro prescribing information, sections 8.1 and 13.1; August 2026

Sources reviewed 2026-10-11. Study and publication dates are stated separately where known.

Up next
What if enthusiasm moves faster than tolerability?

Subject One is fictional. Separate studies, species and populations are not a single patient’s experience. How to read the story